OliX Pharma Amends Paid-in Capital Increase
올릭스
226950
Signal Score
Historical Avg Return (5d)
+0.25%
Data Coverage
100%n=2486
Risk-adjusted indicator based on 2486 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Payment Date: July 8, 2026 (Changed from July 10, 2026)
- • New Share Listing Date: July 24, 2026 (Changed from July 28, 2026)
- • Premium Rate for Issuance Price: 6.912%
- • Issuance Type: Third-Party Allotment to BOLD (Business Opportunities for L'Oreal Development)
AI Analysis Summary
OliX Pharmaceuticals announced an amendment to its Material Fact Report regarding a paid-in capital increase. The key changes include an adjusted payment date to July 8, 2026 (previously July 10, 2026) and an earlier new share listing date of July 24, 2026 (previously July 28, 2026). This third-party allotment to BOLD (Business Opportunities for L'Oreal Development) applies a 6.912% premium rate to the issuance price. The amendment primarily concerns schedule adjustments for an already decided capital increase, indicating a neutral short-term financial impact.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.